CompletedInterventionalPhase 2Last updated Jun 30, 2022

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension

Overview

ClinicalTrials.gov ID: NCT04488978
Lead Sponsor: Handok Inc.INDUSTRY
Brief Summary: A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension
Study Type: Interventional

Status

Overall Status: Completed
Start Date: May 21, 2020Actual
Primary Completion Date: Nov 9, 2021Actual
Completion Date: Nov 9, 2021Actual

Study Record Dates

First Submitted: Jul 21, 2020
First Submitted that Met QC Criteria: Jul 24, 2020
First Posted: Jul 28, 2020Actual
Last Update Submitted that Met QC Criteria: Jun 28, 2022
Last Update Posted: Jun 30, 2022Actual
Last Verified: Jun 2022

NCT05476354Completed

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

NCT05475665Completed

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

NCT00425373Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

NCT00950066Completed

Irbesartan and Amlodipine Combination in Controlling Blood Pressure

NCT00942344Completed

Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension

NCT00437645Completed

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension